EPHA3 and neoplasm: In particular, EphA2, EphA3, EphA4, and EphB4 are promising therapeutic candidates, based on increased expression in tumours and the TME, and drugs targeting these receptors have shown some promise in tumour models, with mixed success in the limited clinical studies performed to date.